Parallax Volatility Advisers’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-121,100
Closed -$1.34M 2714
2023
Q2
$1.34M Buy
121,100
+91,900
+315% +$1.28M ﹤0.01% 1284
2023
Q1
$392K Buy
29,200
+28,900
+9,633% +$500K ﹤0.01% 1801
2022
Q4
$3.71K Sell
300
-1,500
-83% -$21.2K ﹤0.01% 2664
2022
Q3
$25K Sell
1,800
-58,100
-97% -$936K ﹤0.01% 2710
2022
Q2
$827K Buy
+59,900
New +$959K ﹤0.01% 1706
2021
Q1
Sell
-5,400
Closed -$130K 2247
2020
Q4
$130K Sell
5,400
-600
-10% -$19.9K ﹤0.01% 1925
2020
Q3
$246K Buy
6,000
+3,900
+186% +$179K ﹤0.01% 2478
2020
Q2
$104K Buy
+2,100
New +$162K ﹤0.01% 2380
2019
Q1
Sell
-31,500
Closed -$3.17M 4296
2018
Q4
$3.17M Buy
31,500
+25,000
+385% +$2.59M ﹤0.01% 874
2018
Q3
$821K Buy
+6,500
New +$688K ﹤0.01% 1326
2017
Q4
Sell
-50,000
Closed -$2.9M 5136
2017
Q3
$2.9M Buy
+50,000
New +$5.39M ﹤0.01% 731
2017
Q1
Sell
-5,000
Closed -$543K 4878
2016
Q4
$543K Hold
5,000
﹤0.01% 1471
2016
Q3
$823K Hold
5,000
﹤0.01% 1322
2016
Q2
$713K Buy
+5,000
New +$729K ﹤0.01% 1324

Other funds holding ICPT

Parallax Volatility Advisers's ICPT Position: Q2 2023 in Review

Parallax Volatility Advisers sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2023, closing a stake of 275 shares — an estimated $3.83K sold.

Parallax Volatility Advisers first reported a position in ICPT in Q4 2015 and held it in 17 quarters. The position peaked at $2.04M in Q4 2021. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

  • Parallax Volatility Advisers reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 275 Intercept Pharmaceuticals, Inc. shares in Q2 2023, an estimated $3.83K.
  • Parallax Volatility Advisers first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2015 and held it in 17 quarters.
  • Parallax Volatility Advisers's Intercept Pharmaceuticals, Inc. position peaked at $2.04M in Q4 2021.
  • 126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on Parallax Volatility Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.